# Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

> **NCT02141542** · PHASE1 · COMPLETED · sponsor: **F. Stephen Hodi, MD** · enrollment: 15 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Tremelimumab
- **DRUG:** MEDI3617

## Key facts

- **NCT ID:** NCT02141542
- **Lead sponsor:** F. Stephen Hodi, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2020-09-23
- **Final completion:** 2020-09-23
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02141542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02141542, "Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02141542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*